polymerase-ii

FIT-039 是一种选择性和 ATP 竞争性的口服活性 CDK9 抑制剂，对CKD9 cyclin T1的IC50为 5.8 μM。它抑制HSV-1(IC50为 0.69 μM)，HSV-2，人腺病毒和人CMV 的复制。它可抑制耐药性HSV 和其他 DNA 病毒，是有前途的抗病毒药物。

ML-60218 是广谱 RNA pol III 抑制剂，对酿酒酵母和人类的 IC50 分别为 32 和 27 μM。 ML-60218 会破坏已组装的病毒质并阻碍新病毒质的形成。

RNA polymerase II-IN-1（compound 19iv）是一款鹅膏毒素类化合物，能够抑制RNA聚合酶II（Pol II），其半抑制浓度IC50为36.66 nM。该化合物相较于α-Amanitin，对癌细胞展现出更高的细胞毒性，而对正常细胞的毒性较低。

RNA polymerase II-IN-2 (compound 20iii)是高效的RNA polymerase II (Pol II)抑制剂，其Ki值为74.1 nM。该化合物对癌细胞展现出细胞毒性，其对CHO和HEK293细胞的毒性分别为α-amanitin的2倍和5倍。

AOH1996 是一种具有口服活性的复制体组分 PCNA (增殖细胞核抗原) 配体，靶向转录-复制冲突 (TRC)。AOH1996 可干扰 PCNA 与其结合蛋白的相互作用，导致 DNA 复制应激，诱导细胞凋亡 (apoptosis)。AOH1996 通过稳定 PCNA 和 RNA 聚合酶 II 的相互作用从而导致蛋白酶体依赖的 rpb1 降解和致命的 DNA 损伤。AOH1996 与 DNA 损伤剂具有协同作用，可抑制肿瘤细胞生长。

(S)-Enitociclib (VIP152) 是一种选择性 CDK9 抑制剂，通过抑制 RNA 聚合酶 II 介导的转录来诱导 MYC+ 淋巴瘤的完全消退，抑制抗凋亡和促生存蛋白的转录。

A09-003 是一种新型细胞周期蛋白依赖性激酶-9 CDK-9 抑制剂。A09-003 能够抑制多种白血病细胞系的增殖，抑制hi髓系细胞白血病序列-1蛋白增加。A09-003还能诱导细胞凋亡，降低 RNA 聚合酶 II 活性，降低 Mcl-1 表达。

AZD-4573 is a selective and short-acting inhibitor of the serine threonine cyclin-dependent kinase 9, the catalytic subunit of the RNA polymerase II elongation factor positive transcription elongation factor b. It also has a potential antineoplastic activ

Mycophenolic acid-d3 (Mycophenolate-d3) 是 Mycophenolic acid 的衍生物。Mycophenolic acid 是一种降低GTP 水平和损害RNA 聚合酶II (RNAP II)转录延伸的化合物，促进了近端位点的使用，能够逆转虫草素对选择性聚腺苷化的作用。

β-Amanitin, a cyclic peptide toxin found in the poisonous Amanita phalloides mushroom, inhibits eukaryotic RNA polymerase II and III, thereby disrupting protein synthesis.

Mal-C6-α-Amanitin is a drug-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.

5-formylcytosine (5FC) is a rare base found in mammalian DNA. It participates in active DNA demethylation, changes DNA double helix structure, and reduces the transcription rate and substrate specificity of RNA polymerase II.

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity. One vial of this peptide may be used as a methyltransferase acceptor peptide for more than 200 reactions at 15 μM.

cDPCP is a platinum-containing DNA-crosslinking agent.1Unlike cisplatin or oxaliplatin , cDPCP forms monofunctional DNA adducts. It is transported into cells by organic cation transporter 1 (OCT1) and OCT2, inhibiting proliferation of MDCK cells expressing the human transporters with IC50values of 8.1 and 1.5 μM, respectively. cDPCP inhibits RNA polymerase II-mediated transcription in a reporter assay using HeLa cells. It increases survival in murine S180 sarcoma and P388 leukemia models when administered at doses of 40 and 80 mg/kg, respectively.2 1.Lovejoy, K.S., Todd, R.C., Zhang, S., et al.cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsProc. Natl. Acad. Sci. USA105(26)8902-9807(2008) 2.Hollis, L.S., Amundsen, A.R., and Stern, E.W.Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+J. Med. Chem.32128-136(1989)

γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin.

ε-Amanitin is a cyclic peptide obtained from various mushroom species. It exhibits a strong affinity for RNA polymerase II and effectively inhibits its activity.

Thio-ITP, also known as 6-Thioinosine 5'-triphosphate, is a competitive inhibitor of RNA polymerase activity. It exhibits a strong apparent affinity towards the polymerases, with Ki values of 40.9 μM for RNA polymerase I and 38.0 μM for RNA polymerase II.

POL1-IN-1 (Compound 3A) 是一种RNA 聚合酶 1 POL1抑制剂，IC50值低于 0.5 uM。 它能有效抑制A375恶性黑色素瘤细胞系中RNA 聚合酶I 的转录。

CDK-IN-9 (compound 24) 是一种 CDK 的有效抑制剂。CDK-IN-9 也是一种能够诱导 CDK12 和 DDB1 相互作用的分子胶， 能够作用于 CDK2 E (IC50: 4 nM) 。CDK-IN-9 能够导致细胞周期蛋白 K (cyclin K) 的多泛素化及其随后的降解。CDK-IN-9 可以利用去磷酸化视网膜母细胞瘤蛋白和RNA 聚合酶 II，进而诱导细胞凋亡 (apoptosis)。

CDK7-IN-2 是 CDK7 的有效抑制剂。其中 CDK7 利用 RNA 聚合酶 II (RNAPII) 的 Rbpl 亚基的磷酸化参与转录起始过程，其与细胞周期和转录活性的时间控制有关。CDK7 对癌症疾病，尤其是侵袭性和难以治疗的癌症具有研究潜力。

BSJ-01-175 是选择性的、有效的 CDK12 13 共价抑制剂。BSJ-01-175 对癌细胞具有显著的选择性，对磷酸化RNA 聚合酶 II 表现出有效抑制作用，并能够显著下调 CDK12 靶向基因。

Pidnarulex HCl is the salt form of CX-5461, a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage. CX-5461 selectively inhibits rRNA synthesis by Pol I in the nucleolus, but does not inhibit mRNA synthesis by RNA Polymerase II (Pol II) and does not inhibit DNA replication or protein synthesis. Inhibition of Pol I results in nucleolar stress and release of ribosomal proteins (RP) from the nucleolus. The RP bind to Mdm2 and liberate p53 to orchestrate apoptosis in cancer cells. CX-5461 demonstrates a favorable preclinical profile, potently and selectively kills cancer cells, demonstrates robust in vivo efficacy in multiple models, and has demonstrated oral bioavailability in multiple species.

MFH290 is a novel cysteine (Cys)-directed covalent inhibitor of CDK12 13. MFH290 forms a covalent bond with Cys-1039 of CDK12, exhibits excellent kinome selectivity, inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II), and reduces the expression of key DNA damage repair genes. Importantly, these effects were demonstrated to be CDK12-dependent as mutation of Cys-1039 rendered the kinase refractory to MFH290 and restored Pol II CTD phosphorylation and DNA damage repair gene expression. Consistent with its effect on DNA damage repair gene expression, MFH290 augments the antiproliferative effect of the PARP inhibitor olaparib.

Epolactaene is a neuritogenic compound in human neuroblastoma cells which selectively inhibit the activities of mammalian DNA polymerases and human DNA topoisomerase II.